# Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst

Source: https://onco.cc/trials/nct06727565/  
OnCo record `nct06727565` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Domvanalimab, Zimberelimab, Paclitaxel / nab-paclitaxel in head and neck squamous cell carcinoma, run by Gilead Sciences, active and no longer recruiting.

## Summary

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 is a phase 2 interventional study registered as NCT06727565 by Gilead Sciences, with 39 participants enrolled, started 2025-02-18 and due to reach its primary completion in 2027-03. Interventions recorded: Domvanalimab, Zimberelimab, Paclitaxel, Carboplatin. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06727565
- Phase: 2
- Setting: VELOCITY-HNSCC Substudy-01: A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status
- Sponsor: Gilead Sciences
- Enrolled: 39

## Sources

- ClinicalTrials.gov NCT06727565: https://clinicaltrials.gov/study/NCT06727565

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Domvanalimab](https://onco.cc/drugs/domvanalimab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/), [Zimberelimab](https://onco.cc/drugs/zimberelimab/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct06727565.json